Physician profile
Munveer S Bhangoo
NPI 1235499518
$803,722.09
in general payments reported to CMS, 2019-2025
64 companies · $83K in 2025
The $83K reported for 2025 was more than what 97% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24K · 2020: $30K · 2021: $177K · 2022: $217K · 2023: $191K · 2024: $83K · 2025: $83K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $191K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $78K · Consulting Fee: $70K · Food and Beverage: $9,422 · Travel and Lodging: $8,113 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $191,481.25 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $77,550.00 |
| Consulting Fee | $69,898.75 |
| Food and Beverage | $9,422.13 |
| Travel and Lodging | $8,113.39 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $266,518.12 | 2019-2025 | Opdivo, Opdualag |
| Exelixis INC. | $265,703.65 | 2019-2025 | Cabometyx |
| Foundation Medicine, INC. | $146,610.00 | 2021-2023 | Foundationone Cdx |
| F. Hoffmann-La Roche Ag | $47,714.00 | 2022-2024 | |
| Astellas Pharma US INC | $15,527.98 | 2023-2025 | Padcev, Xospata, Cresemba |
| Pfizer INC. | $12,662.89 | 2021-2025 | |
| Genentech USA, INC. | $10,605.86 | 2019-2024 | Tecentriq Hybreza, Tecentriq |
| Astrazeneca Pharmaceuticals Lp | $7,629.25 | 2019-2025 | Imjudo, Imfinzi |
| Eisai INC. | $5,778.12 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $5,192.15 | 2022-2025 | |
| Seagen INC. | $3,520.79 | 2019-2023 | Padcev |
| Janssen Biotech, INC. | $3,297.08 | 2021-2025 | Erleada, Darzalex, Tecvayli |
| Glaxosmithkline, LLC. | $2,198.58 | 2021-2025 | Jemperli, Zejula |
| Celgene Corporation | $1,941.33 | 2022-2025 | Opdivo, Pomalyst, Reblozyl |
| Takeda Pharmaceuticals U.S.A., INC. | $1,865.23 | 2023-2024 | Alunbrig, Ninlaro |
Show all 63 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Munveer Bhangoo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.